Novel Early Pregnancy Multimarker Screening Test for Preeclampsia Risk Prediction
暂无分享,去创建一个
K. Fischer | M. Laan | K. Kisand | K. Rull | Triin Kikas | Ele Hanson | K. Ratnik | Oliver Aasmets | O. Aasmets
[1] F. Jehee,et al. Clinical impact of additional findings detected by genome-wide non-invasive prenatal testing: Follow-up results of the TRIDENT-2 study , 2022, American journal of human genetics.
[2] L. Sobrevia,et al. Using Machine Learning to Predict Complications in Pregnancy: A Systematic Review , 2022, Frontiers in Bioengineering and Biotechnology.
[3] S. Cicero,et al. Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia , 2021, Circulation.
[4] K. Devriendt,et al. Outcome of publicly funded nationwide first-tier noninvasive prenatal screening , 2021, Genetics in Medicine.
[5] M. Laan,et al. C-allele of rs4769613 Near FLT1 Represents a High-Confidence Placental Risk Factor for Preeclampsia , 2020, Hypertension.
[6] D. Sahota,et al. First trimester preeclampsia screening and prediction. , 2020, American journal of obstetrics and gynecology.
[7] Meiyuan Jin,et al. Association between pentraxin-3 and the risk of preeclampsia , 2020, Medicine.
[8] M. Laan,et al. Single-Tube Multimarker Assay for Estimating the Risk to Develop Preeclampsia. , 2020, The journal of applied laboratory medicine.
[9] Andrea Montanari,et al. Early prediction of preeclampsia via machine learning. , 2020, American journal of obstetrics & gynecology MFM.
[10] H. Stepan,et al. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia , 2020, Hypertension.
[11] L. Raio,et al. FIRST TRIMESTER SCREENING FOR PREECLAMPSIA – A SYSTEMATIC REVIEW , 2019, Hypertension in pregnancy.
[12] L. Chappell,et al. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. , 2019, BMJ.
[13] Yejin Park,et al. Prediction model development of late-onset preeclampsia using machine learning-based methods , 2019, PloS one.
[14] A. Staff. The two-stage placental model of preeclampsia: An update. , 2019, Journal of reproductive immunology.
[15] K. Nicolaides,et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[16] Yanming Feng,et al. Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA , 2019, Nature Medicine.
[17] A. Papageorghiou,et al. ISUOG Practice Guidelines: role of ultrasound in screening for and follow‐up of pre‐eclampsia , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[18] L. Magee,et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. , 2018, Pregnancy hypertension.
[19] Nicola Persico,et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia , 2017, The New England journal of medicine.
[20] D. Lawlor,et al. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia , 2017 .
[21] S. Cicero,et al. Accuracy of competing‐risks model in screening for pre‐eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation , 2017, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[22] L. Sentilhes,et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. , 2017, New England Journal of Medicine.
[23] S. Brennecke,et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.
[24] D. Wright,et al. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. , 2015, American journal of obstetrics and gynecology.
[25] L. Magee,et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. , 2014, Pregnancy hypertension.
[26] I. Sargent,et al. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? , 2014, Placenta.
[27] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[28] R. Hoover,et al. Maternal angiogenic profile in pregnancies that remain normotensive. , 2011, European journal of obstetrics, gynecology, and reproductive biology.
[29] H. Stepan,et al. Relation Between Maternal Angiogenic Factors and Utero-Placental Resistance in Normal First- and Second-Trimester Pregnancies , 2011, Hypertension in pregnancy.
[30] François Audibert,et al. Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy: A Meta-Analysis , 2010, Obstetrics and gynecology.
[31] George G Klee,et al. Antibody-based protein multiplex platforms: technical and operational challenges. , 2010, Clinical chemistry.
[32] A. Papageorghiou,et al. First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction , 2009, Acta obstetricia et gynecologica Scandinavica.
[33] F. Schmidt. Meta-Analysis , 2008 .
[34] K. Johnson. An Update. , 1984, Journal of food protection.